<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8723">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00810511</url>
  </required_header>
  <id_info>
    <org_study_id>P-335-C-007</org_study_id>
    <nct_id>NCT00810511</nct_id>
  </id_info>
  <brief_title>Evaluation of Two Silicone Hydrogel Lenses Over a One Month Period</brief_title>
  <official_title>Evaluation of Two Silicone Hydrogel Lenses Over a One Month Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CIBA VISION</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to compare two different contact lenses during 4 weeks of wear.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Comfort at End of Day</measure>
    <time_frame>After 4 weeks of wear</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluated by the subject as a single, retrospective evaluation of 4-week wear time. Measured on a 10-point scale, with 1 being poor and 10 being excellent.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Myopia</condition>
  <arm_group>
    <arm_group_label>Lotrafilcon A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Investigational, spherical, silicone hydrogel contact lenses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comfilcon A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercially marketed, spherical, silicone hydrogel contact lenses</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotrafilcon A contact lens</intervention_name>
    <description>Silicone hydrogel contact lens</description>
    <arm_group_label>Lotrafilcon A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Comfilcon A contact lens</intervention_name>
    <description>Silicone hydrogel contact lens</description>
    <arm_group_label>Comfilcon A</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current soft contact lens wearer who wear their habitual lenses for no less than 10
             hours a day, 5 days a week

          -  Have a need for correction in both eyes and be correctable to at least 20/40 distance
             vision in each eye while wearing trial lenses

          -  Replace lenses on a weekly or longer schedule

          -  Other protocol inclusion/exclusion criteria may apply

        Exclusion Criteria:

          -  Requires concurrent ocular medication

          -  Eye injury or surgery within twelve weeks immediately prior to enrollment

          -  Evidence of systemic or ocular abnormality, infection, or disease likely to affect
             successful wear of contact lenses or use of their accessory solutions

          -  Current soft toric lens wearers

          -  Those who dispose of their soft lenses on a daily basis

          -  Current NIGHT &amp; DAY® or Biofinity® lens wearers

          -  Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>January 2012</verification_date>
  <lastchanged_date>June 26, 2012</lastchanged_date>
  <firstreceived_date>December 17, 2008</firstreceived_date>
  <firstreceived_results_date>July 23, 2010</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Lotrafilcon A</title>
          <description>Investigational, spherical, silicone hydrogel contact lenses</description>
        </group>
        <group group_id="P2">
          <title>Comfilcon A</title>
          <description>Commercially marketed, spherical, silicone hydrogel contact lenses</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>death in the family</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>deposits on contact lens</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Lotrafilcon A</title>
          <description>Investigational, spherical, silicone hydrogel contact lenses</description>
        </group>
        <group group_id="B2">
          <title>Comfilcon A</title>
          <description>Commercially marketed, spherical, silicone hydrogel contact lenses</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="107"/>
                <measurement group_id="B2" value="106"/>
                <measurement group_id="B3" value="213"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="10"/>
                <measurement group_id="B3" value="21"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="96"/>
                <measurement group_id="B2" value="96"/>
                <measurement group_id="B3" value="192"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="30.6" spread="9.8"/>
                <measurement group_id="B2" value="31.8" spread="11.0"/>
                <measurement group_id="B3" value="31.2" spread="10.4"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="84"/>
                <measurement group_id="B2" value="84"/>
                <measurement group_id="B3" value="168"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="23"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="45"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="107"/>
                <measurement group_id="B2" value="106"/>
                <measurement group_id="B3" value="213"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Comfort at End of Day</title>
        <description>Evaluated by the subject as a single, retrospective evaluation of 4-week wear time. Measured on a 10-point scale, with 1 being poor and 10 being excellent.</description>
        <time_frame>After 4 weeks of wear</time_frame>
        <safety_issue>No</safety_issue>
        <population>One subject in the Lotrafilcon A arm was excluded from efficacy analysis due to a protocol deviation.</population>
        <group_list>
          <group group_id="O1">
            <title>Lotrafilcon A</title>
            <description>Investigational, spherical, silicone hydrogel contact lenses</description>
          </group>
          <group group_id="O2">
            <title>Comfilcon A</title>
            <description>Commercially marketed, spherical, silicone hydrogel contact lenses</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="96"/>
                  <measurement group_id="O2" value="102"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Comfort at End of Day</title>
            <description>Evaluated by the subject as a single, retrospective evaluation of 4-week wear time. Measured on a 10-point scale, with 1 being poor and 10 being excellent.</description>
            <units>Scale of 1-10</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="6.5" spread="2.4"/>
                  <measurement group_id="O2" value="6.9" spread="2.4"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks, duration of the study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Lotrafilcon A</title>
          <description>Investigational, spherical, silicone hydrogel contact lenses</description>
        </group>
        <group group_id="E2">
          <title>Comfilcon A</title>
          <description>Commercially marketed, spherical, silicone hydrogel contact lenses</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="107"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>For a period of 10 years, the clinical investigator must hold all trial-related information and documents confidential and must agree to obtain sponsor's written consent before discussing, presenting, publicizing, or otherwise disclosing any preclinical and/or clinical data or impressions from this trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Priya Janakiraman, OD, FAAO / Head, Global Clinical Affairs</name_or_title>
      <organization>CIBA VISION</organization>
      <phone>1-800-241-7629</phone>
      <email>priya.janakiraman@cibavision.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
